Pelvic inflammatory disease is an infection of the female reproductive organs. The pelvis includes the ovaries, cervix, fallopian tubes, and uterus. Different types of bacteria can cause this disease, including some bacteria that cause chlamydia and gonorrhea. The bacteria first enters the vagina causing infection and can move to the pelvic organs. If the infection spreads to the blood, pelvic inflammatory disease can become life-threatening. Antibiotics are generally used to treat this disease; however, in case of rupturing of an abscess the patient might require surgery. Men could be the silent carriers of bacteria, hence, in recurrent cases of pelvic inflammatory disease in a woman, it is suggested for the male partner to undergo treatment simultaneously.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the pelvic inflammatory disease treatment market.
Top Impacting Factors
Rise in awareness of the pelvic inflammatory disease among females is increasing the diagnosis rate of the disease, thereby resulting in an increased number of women getting treated for the same.
Furthermore, the first-line treatment of pelvic inflammatory disease involves the use of oral and intramuscular treatment routes, which is why the adoption rate for these treatments is high. This acts as a key growth driver of the global market.
The population of women between the age of 20–24 years is increasing across the world. This age group is known to be the fertile age group and has an increased risk of developing pelvic inflammatory diseases. Hence, it is one of the factors that is propelling the growth of the pelvic inflammatory disease treatment market.
However, the use of preventative methods and misdiagnosis of the disease can impede the market growth during the forecast period. In addition, the risk of the development of resistant microorganisms strains can come up as a challenge for the growth of the pelvic inflammatory disease treatment market.
Key Market Trends
The tetracycline drugs are anticipated to dominate the pelvic inflammatory disease treatment industry. The growth of this segment can be attributed to rise in tetracycline prescriptions, as the drug has proven efficacy in the treatment of cephalosporin.
Some prominent players in the market such as Mayne Pharma and Pfizer, Inc. are making acquisitions and launching new products to consolidate their market positions across the globe. Some of the companies dominating the market are Perrigo Company Plc, Bristol-Myers Squibb Company, and Mylan NN.
North America is expected to dominate the pelvic inflammatory disease treatment market during the forecast period. This dominance is anticipated due to rise in incidence of menopausal disorders, uterine fibroids, endometriosis, trichomoniasis, HIV/AIDS, and polycystic ovary syndrome, due to the change in lifestyles and rise in stress among females in the U.S.
Key Benefits of the Report
- This study presents the analytical depiction of the pelvic inflammatory disease treatment industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the pelvic inflammatory disease treatment market share.
- The current market is quantitatively analyzed to highlight the growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the pelvic inflammatory disease treatment market. .
- The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
Questions Answered in the Pelvic Inflammatory Disease Treatment Report
- Which are the leading players active in the pelvic inflammatory disease treatment pelvic inflammatory disease treatment market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the pelvic inflammatory disease treatment market in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What are the impacts of COVID-19 in the industry?
- What is pelvic inflammatory disease?
- What is the pelvic inflammatory disease treatment market prediction in the future?
- What are the current trends and predicted trends?
Pelvic Inflammatory Disease Treatment Market Report Highlights
| Aspects | Details |
 By Drug Class |
|
 By Route of Administration |
|
 By End User |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | AstraZeneca, F. Hoffmann-La Roche Ltd, Bristol Myers Squibb Company, Pfizer Inc., Teva Pharmaceutical Industries Ltd, Janssen Pharmaceuticals, Inc., Mayne Pharma Group Limited, Johnson and Johnson Services Inc, Sanofi, Merck & Co., Inc, Mylan N.V. |
Loading Table Of Content...
